The use of heat treatment to eliminate drug interactions due to grapefruit juice

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 11, 2006, Pages 2274-2278

  Uesawa, Yoshihiro ^a   Mohri, Kiminori ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Furanocoumarin; Grapefruit juice; Heat treatment; Nifedipine; Pharmacokinetic interaction

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; BERGAMOTTIN; BERGAPTROL; CYTOCHROME P450 3A; FUROCOUMARIN DERIVATIVE; NIFEDIPINE; SODIUM CHLORIDE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; DUODENUM; ENZYME ACTIVITY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEAT TREATMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; OXIDATION; RAT; TEMPERATURE DEPENDENCE;

ANIMALS; AREA UNDER CURVE; BEVERAGES; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; DUODENUM; FOOD-DRUG INTERACTIONS; HEAT; HYDROXYTESTOSTERONES; INTUBATION, GASTROINTESTINAL; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NIFEDIPINE; PSORALENS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 33750632533     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.2274     Document Type: Article

References (26)

1. Bailey D. G., Spence J. D., Edgar B., Bayliff C. D., Arnold J. M., Clin. Invest. Med., 12, 357-362 (1989).
2. Bailey D. G., Dresser G. K., Am. J. Cardiovasc. Drugs, 4, 281-297 (2004).
3. Kane G. C., Lipsky J. J., Mayo Clin. Proc., 75, 933-942 (2000).
4. Sagir A., Schmitt M., Dilger K., Häussinger D., Digestion, 68, 41-48 (2003).
5. Mohri K., Uesawa Y., Pharm. Res., 18, 177-182 (2001).
6. Goosen T. C., Cillié D., Bailey D. G., Yu C., He K., Hollenberg P. F., Woster P. M., Cohen L., Williams J. A., Rheeders M., Dijkstra H. P., Clin. Pharmacol. Ther., 76, 607-617 (2004).
7. Malhotra S., Bailey D. G., Paine M. F., Watkins P. B., Clin. Pharmacol. Ther., 69, 14-23 (2001).
8. Kakar S. M., Paine M. F., Stewart P. W., Watkins P. B., Clin. Pharmacol. Ther., 75, 569-579 (2004).
9. Paine M. F., Criss A. B., Watkins P. B., J. Pharmacol. Exp. Ther., 312, 1151-1160 (2005).
10. He K., Iyer K. R., Hayes R. N., Sinz M. W., Woolf T. F., Hollenberg P. F., Chem. Res. Toxicol., 11, 252-259 (1998).
11. Paine M. F., Criss A. B., Watkins P. B., Drug Metab. Dispos. Biol. Fate Chem., 32, 1146-1153 (2004).
12. Uesawa Y., Mohri K., Biol. Pharm. Bull., 29, 1286-1289 (2006).
13. Paine M. F., Widmer W. W., Hart H. L., Pusek S. N., Beavers K. L., Criss A. B., Brown S. S., Thomas B. F., Watkins P. B., Am. J. Clin. Nutr., 83, 1097-1105 (2006).
14. Uesawa Y., Mohri K., Yakugaku Zasshi, 125, 875-879 (2005).
15. Ameer B., Weintraub R. A., Clin. Pharmacokinet., 33, 103-121 (1997).
16. Row E. C., Brown S. A., Stachulski A. V., Lennard M. S., Org. Biomol. Chem., 4, 1604-1610 (2006).
17. Ohnishi A., Matsuo H., Yamada S., Takanaga H., Morimoto S., Shoyama Y., Ohtani H., Sawada Y., Br. J. Pharmacol., 130, 1369-1377 (2000).
18. Lakshmi V., Prakash D., Paj K., Kapil R. S., Popli S. P., Phytochemistry, 23, 2629-2631 (1984).
19. Bussey C., Lepoittevin J.-P., Benezra C., Bioorg. Med. Chem. Lett., 3, 1283-1286 (1993).
20. El-Tawil B. A. H., Baghlaf A. O., Barbood S. O., Pharmazie, 35, 503 (1980).
21. Guengerich F. P., Kim D. H., Carcinogenesis, 11, 2275-2279 (1990).
22. Uesawa Y., Mohri K., Yakugaku Zasshi, 125, 889-893 (2005).
23. Mohri K., Uesawa Y., Sagawa K., Drug Metab. Dispos. Biol. Fate Chem., 28, 482-486 (2000).
24. Mohri K., Uesawa Y., Pharm. Res., 18, 1232-1236 (2001).
25. Lown K. S., Bailey D. G., Fontana R. J., Janardan S. K., Adair C. H., Fortlage L. A., Brown M. B., Guo W., Watkins P. B., J. Clin. Invest., 99, 2545-2553 (1997).
26. Bailey D. G., Arnold J. M., Strong H. A., Munoz C., Spence J. D., Clin. Pharmacol. Ther., 54, 589-594 (1993).